Votisposis - Company finances
|
EUR
|
2019
From: 2019-11-14
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | - | 1,776,000 | 1,571,460 | 1,061,288 | 513,663 | 689,105 | 1,385,255 |
| Profit before tax | -1,122 | 57,949 | 18,817 | -62,509 | -87,814 | -3,186 | 158,357 |
| Net profit | -1,122 | 47,923 | 8,728 | -62,509 | -87,814 | -6,480 | 139,240 |
| Equity | 1,378 | 49,301 | 58,029 | -4,480 | -92,294 | -98,774 | 40,466 |
| Liabilities | 214,314 | 1,297,412 | 395,316 | 318,832 | 364,375 | 495,756 | 934,448 |
| Non-current assets | 0 | 0 | 23,500 | 15,667 | 7,833 | 0 | 0 |
| Current assets | 215,692 | 1,346,713 | 429,845 | 298,685 | 264,248 | 396,982 | 974,914 |
| Total assets | 215,692 | 1,346,713 | 453,345 | 314,352 | 272,081 | 396,982 | 974,914 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 11,960 | 141 | 56,150 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | - | -11.5% | -32.5% | -51.6% | +34.2% | +101.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -0.5% | 3.6% | 1.9% | -19.9% | -32.3% | -1.6% | 14.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -81.4% | 97.2% | 15.0% | - | - | - | 344.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 2.7% | 0.6% | -5.9% | -17.1% | -0.9% | 10.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 3.3% | 1.2% | -5.9% | -17.1% | -0.5% | 11.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 155.5 | 26.3 | 6.8 | - | - | - | 23.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 1,776,000 | 1,571,460 | 1,061,288 | 513,663 | 689,105 | 1,385,255 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Votisposis - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-12-16 | 2025-12-18 | 258.10 |
| 2024-04-16 | 2024-04-18 | 269.78 |
| 2023-08-17 | 2023-08-22 | 10.76 |
Votisposis - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-08-16 | 2026-08-19 | 102.53 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Votisposis, UAB (code 305337355) is a private limited liability company engaged in wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, revenue reached €1.39M and net profit amounted to €139.2K, resulting in a 10.1% profit margin. The company moved from a loss-making position in 2023 and 2024, when revenue was €513.7K and €689.1K respectively, and net profit was -€87.8K in 2023 and -€6.5K in 2024. Revenue increased by 101.0% year on year in 2025 and by 169.7% over two years, showing a strong expansion trend. The balance sheet also strengthened: total assets rose to €974.9K in 2025 from €397.0K in 2024 and €272.1K in 2023. Equity turned positive at €40.5K after two years of negative equity, while liabilities increased to €934.4K. Asset turnover stood at 1.42x, and revenue per employee was €1.39M. Return on equity was elevated, reflecting the limited equity base.